Elliott Won't Change Mind On Pharma. Merger

Jan 2 2014 | 11:48am ET

Elliott Management still has a week to tender its shares in pharmaceutical distributor Celesio, a move that would ensure that rival McKesson's US$8.3 billion offer for the company would succeed. But the activist hedge fund had no early Christmas presents for McKesson.

Elliott, which first announced its plans to block the merger earlier last month, reiterated its opposition on Dec. 23. "To be absolutely clear, Elliott's final, binding decision is not to accept McKesson's offer on its current terms."

The New York-based hedge fund made the statement following "reports suggesting that it will change its mind and accept McKesson's offer."

"These reports are categorically incorrect," Elliott said.

The hedge fund owns about 22.7% of Celesio's diluted stock, which should enable it to block the deal; McKesson has set a 75% hurdle for the merger to go through. It has said that the current price does not offer "fair compensation to all Celesio shareholders and bondholders," and has suggested splitting Celesio by selling its wholesale and pharmacy businesses separately.


In Depth

Exotic Assets: Investing In Rare Violins

Jan 17 2017 | 4:43pm ET

By definition, alternative investments include exotic assets far beyond your typical...

Lifestyle

'Tis the Season: Wall Street Holiday Parties Back In Fashion

Dec 22 2016 | 9:23pm ET

Spending on Wall Street holiday parties has largely returned to pre-2008 levels...

Guest Contributor

The Trump Administration: What It Could Mean for Carried Interest

Jan 19 2017 | 5:25pm ET

The arrival of the Trump administration brings the potential for a repeal of the...

 

From the current issue of

Often seen as a passion project, or part of a philanthropic venture, rare and fine stringed instruments offer an exciting option to diversify one’s investment portfolio while providing an opportunity for an exceptional long-term investment.